Literature DB >> 11451698

In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

E J Goldstein1, G Conrads, D M Citron, C V Merriam, Y Warren, K Tyrrell.   

Abstract

The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (< or =0.125 microg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 microg/ml; and all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by < or =0.125 microg/ml. Among the anaerobes tested, only fusobacteria (45%) required > or =4 microg of ABT-773/ml for inhibition. ABT-773 may offer a therapeutic alternative for sinus infections.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11451698      PMCID： PMC90655          DOI： 10.1128/AAC.45.8.2363-2367.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  The in vitro activity of ABT773, a new ketolide antimicrobial agent.

Authors:  J M Andrews; T M Weller; J P Ashby; R M Walker; R Wise
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

2.  In vitro activity of ABT-773 against anaerobic bacteria.

Authors:  E Sillerström; E Wahlund; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

3.  In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; G V Doern; H K Huynh; E M Wingert; P R Rhomberg
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.

Authors:  S Hunt Gerardo; D M Citron; M C Claros; E J Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Resistance to antimicrobials used for therapy of otitis media and sinusitis: effect of previous antimicrobial therapy and smoking.

Authors:  I Brook; A E Gober
Journal:  Ann Otol Rhinol Laryngol       Date:  1999-07       Impact factor: 1.547

7.  Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections.

Authors:  E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

Authors:  C Thornsberry; P Ogilvie; J Kahn; Y Mauriz
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

9.  Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.

Authors:  D M Citron; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Bacteriological findings of acute maxillary sinusitis in young adults.

Authors:  H R Jousimies-Somer; S Savolainen; J S Ylikoski
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948
View more
  3 in total

1.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 3.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.